Shulkes A
Department of Surgery, University of Melbourne, Austin Hospital, Victoria, Australia.
Baillieres Clin Endocrinol Metab. 1994 Jan;8(1):215-36. doi: 10.1016/s0950-351x(05)80232-0.
Somatostatin (SOM) was originally isolated as the hypothalamic inhibitor of growth hormone release but was subsequently shown to have a widespread distribution including the gastrointestinal tract. In fact the gastrointestinal tract contains about 70% of the total body SOM. SOM has inhibitory actions on gastrointestinal exocrine and endocrine secretions, motility and blood flow. Within the gut it functions as an endocrine, paracrine, autocrine and neurocrine factor. SOM is released by a meal, and a number of neurotransmitters and regulatory peptides also influence SOM release. SOM is a key component of the gastrin-acid feedback loop as luminal acid releases SOM, which in turn has inhibitory effects on both gastrin and gastric acid. Consistent with the diverse functions of SOM, a number of different although related SOM receptors with distinct distribution patterns and intracellular mediators have been cloned and sequenced. SOM is the first of the gut regulatory peptides to have a significant therapeutic use. By inhibiting both the target cell (e.g. parietal cell) and the release of the active agent (e.g. gastrin) the therapeutic potential of SOM is magnified. To date most of the clinical experience has been with the one analogue, octreotide. This analogue has a longer half-life than SOM (hours versus minutes) but has only minimal oral activity, therefore requiring subcutaneous injections several times a day. The definite gastrointestinal applications include treatment of gastroenteropancreatic tumours. It is also becoming a favoured treatment for gastrointestinal fistulae, variceal bleeding and diarrhoea. However, octreotide has no consistent effect on tumour growth. The high density of SOM receptors on tumours has allowed localization of tumours using in vivo scintography with labelled octreotide. The sequencing of a variety of SOM receptors with different distributions and differing cellular effector systems raises the likelihood of developing SOM analogues for specific clinical applications.
生长抑素(SOM)最初是作为下丘脑生长激素释放抑制剂被分离出来的,但随后发现它分布广泛,包括胃肠道。实际上,胃肠道含有全身约70%的SOM。SOM对胃肠外分泌和内分泌、运动及血流具有抑制作用。在肠道内,它作为一种内分泌、旁分泌、自分泌和神经分泌因子发挥作用。进食可促使SOM释放,多种神经递质和调节肽也会影响SOM的释放。SOM是胃泌素 - 酸反馈回路的关键组成部分,因为腔内酸会释放SOM,而SOM反过来又对胃泌素和胃酸均有抑制作用。与SOM的多种功能相一致,已克隆并测序了许多不同但相关的SOM受体,它们具有不同的分布模式和细胞内介质。SOM是第一种具有重要治疗用途的肠道调节肽。通过抑制靶细胞(如壁细胞)以及活性剂(如胃泌素)的释放,SOM的治疗潜力得以放大。迄今为止,大多数临床经验都来自一种类似物——奥曲肽。这种类似物的半衰期比SOM长(数小时与数分钟相比),但口服活性极小,因此需要每天皮下注射数次。明确的胃肠道应用包括治疗胃肠胰肿瘤。它也正成为治疗胃肠瘘、静脉曲张出血和腹泻的首选疗法。然而,奥曲肽对肿瘤生长没有一致的作用。肿瘤上高密度的SOM受体使得利用标记奥曲肽的体内闪烁扫描术对肿瘤进行定位成为可能。对具有不同分布和不同细胞效应系统的多种SOM受体进行测序,增加了开发用于特定临床应用的SOM类似物的可能性。